Y-mAbs Therapeutics is a biopharmaceutical company that develops and commercializes antibody-based therapeutic products for cancer treatment. Its products include DANYELZA, a monoclonal antibody for pediatric patients with high-risk neuroblastoma, and Omburtamab, a monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma and other B7-H3 positive tumors. The company is also developing other products for the treatment of small cell lung cancer, medulloblastoma, and solid tumors. Y-mAbs has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology.